ILIAS Biologics Inc. is successfully wrapping up the Phase 1  clinicial trial for our ILB-202, marking a global first in the systemic administration of engineered exosomes. 

This is not merely about ILB-202’s safety validation; it represents a significant human proof-of-concept for our innovative exosome platforms. Additionally, by analyzing PD biomarkers from human blood samples, we will obtain evidence of potential efficacy. 

News Link